.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB15_RopeginterferonAlfa2b.RopeginterferonAlfa2b .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB15_RopeginterferonAlfa2b.RopeginterferonAlfa2b| name: | RopeginterferonAlfa2b |
| ATC code: | L03AB15 | route: | subcutaneous |
| n-compartments | 1 |
Ropeginterferon alfa-2b is a mono-pegylated, long-acting interferon-alpha used primarily in the treatment of polycythemia vera and other myeloproliferative neoplasms. It is currently approved for use in certain countries for treating polycythemia vera.
Pharmacokinetic parameters following subcutaneous administration in adult patients with polycythemia vera.
Miyachi, N, et al., & Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Clinical drug investigation 41(4) 391–404. DOI:10.1007/s40261-021-01026-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33725322
Huang, YW, et al., & Wang, MX (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Advances in therapy 38(9) 4756–4770. DOI:10.1007/s12325-021-01863-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/34328630
Lin, HH, et al., & Chen, PJ (2021). Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH open : an open access journal of gastroenterology and hepatology 5(8) 929–940. DOI:10.1002/jgh3.12613 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34386602